Perrigo Company PLC (TLV:PRGO) said it has acquired a number of over-the-counter products sold in Australia and New Zealand from Aspen Global for $51 million in cash. The maker and distributor of among others OTC and generic prescription pharmaceuticals said the products include Herron analgesics, vitamins and supplements that are primarily sold through the mass retail channel. The products are expected to generate at least $20 million in annual sales. Perrigo Company PLC (TLV:PRGO) stock opened at $57,400.00 in last session, and closed at $57,200.00, while the day range of PROG stock is $57,000.00-$57,690.00.The stock showed a positive weekly performance of 3.45%.
Swiss drug maker Novartis AG (ADR) (NYSE:NVS) said Wednesday it is cutting 361 jobs following the planned closure of a manufacturing plant in the U levitra precio españa.K., as part of a global reorganization of its research-and-development operations. Novartis AG (ADR) (NYSE:NVS) stock opened at $83.62, in last session and closed at $83.18, by gained 0.76%.The 52 week range was $67.55-$84.33.Company’s market capitalization is $202.56 billion.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) SNSS +2.02% announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company’s common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) stock gained2.02% and finished the last session at $6.55.The EPS of the stock remained -0.61.Company’s market capitalization is $353.59 million.
A number of analysts have recently weighed in on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares. Analysts at Piper Jaffray initiated coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday, November 26th. They set an “overweight” rating and a $21.00 price target on the stock. On a related note, analysts at Jefferies Group raised their price target on shares of Vanda Pharmaceuticals from $13.00 to $20.00 in a research note on Friday, November 15th. They now have a “buy” rating on the stock. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock opened the session at $16.05, and closed the session at $15.13.The 52 week range of the VNDA stock remained $3.57-$16.55 and the day range was $14.95-$16.55.